AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27281019 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐alfa‐2a (Peg‐IFN‐α) therapy
Number of subjects: 0
Study 27281019 — intervention group
Group type: COMPARATOR
Intervention: Nucleos(t)ide analog alone or in combination with Peg‐IFN‐α
Number of subjects: 0
Study 24487733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's Lactate (LR)
Number of subjects: 40
Study 24487733 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 40
Study 22385565 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantum BioEnergetics (QBE) healing
Number of subjects: 0
Study 22385565 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0
Study 20604704 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18781090 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI axial length measurement
Number of subjects: 20
Study 18781090 — intervention group
Group type: COMPARATOR
Intervention: A-scan ultrasonography axial length measurement
Number of subjects: 20
Study 15000216 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing of troponin T
Number of subjects: 741
Study 15000216 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing of myoglobin
Number of subjects: 741
Study 15000216 — intervention group
Group type: COMPARATOR
Intervention: Laboratory-based method for troponin T
Number of subjects: 741
Study 12224570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine combined with primaquine (25 mg/kg in 3 doses over 48 hours + 30 mg primaquine daily for 28 days)
Number of subjects: 53
Study 12224570 — intervention group
Group type: COMPARATOR
Intervention: Placebo of primaquine
Number of subjects: 53
Study 12224570 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine combined with primaquine
Number of subjects: 53
Study 9833916 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 169
Study 9833916 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin infusion (250 microg/h after a 250‐microg bolus for 5 days)
Number of subjects: 169
Study 9833916 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin infusion
Number of subjects: 169
Study 7855216 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1 mg) administered daily for 8 days
Number of subjects: 0
Study 7855216 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (single dose)
Number of subjects: 0
Study 7855216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2764595 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia
Number of subjects: 63
Study 2764595 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study 154164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium (Atrovent)
Number of subjects: 25
Study 154164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 31087085 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 61
Study 31087085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 27862658 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (4g in 5% dextrose)
Number of subjects: 12
Study 27862658 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 12
Study 25841959 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% buffered lidocaine with 1:100,000 epinephrine
Number of subjects: 100
Study 25841959 — intervention group
Group type: COMPARATOR
Intervention: 4% lidocaine with 1:100,000 epinephrine (nonbuffered)
Number of subjects: 100
Study 24379592 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin and dexamethasone treatment
Number of subjects: 70
Study 24379592 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition and nasogastric (NG) tube feeding (Control)
Number of subjects: 70
Study 21757237 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized stepwise treatment regimen (SSTR)
Number of subjects: 148
Study 21757237 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 148
Study 19420283 — intervention group
Group type: EXPERIMENTAL
Intervention: medium‐chain triglycerides/long‐chain triglycerides (soybean oil; MCT/LCT)
Number of subjects: 28
Study 19420283 — intervention group
Group type: EXPERIMENTAL
Intervention: olive/soybean oil (oleic)
Number of subjects: 28
Study 19420283 — intervention group
Group type: EXPERIMENTAL
Intervention: long‐chain triglycerides (soybean oil; LCT)
Number of subjects: 28
Study 19420283 — intervention group
Group type: EXPERIMENTAL
Intervention: structured lipid
Number of subjects: 28
Study 19420283 — intervention group
Group type: COMPARATOR
Intervention: Control group (MCT/LCT and oleic groups)
Number of subjects: 28
Study 16883525 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium group (1000 mg element calcium and 400 units of vitamin D daily for 12 months)
Number of subjects: 200
Study 16883525 — intervention group
Group type: COMPARATOR
Intervention: Low calcium group (300 mg element calcium and 300 units of vitamin D daily for 12 months)
Number of subjects: 200
Study 15291652 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medications
Number of subjects: 20
Study 11718088 — intervention group
Group type: EXPERIMENTAL
Intervention: Double autologous hematopoietic stem cell transplantation (DAHSCT)
Number of subjects: 13
Study 9146599 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine plus phentolamine
Number of subjects: 60
Study 9146599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 60
Study 7515652 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 1138
Study 7515652 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 1138
Study 7515652 — intervention group
Group type: EXPERIMENTAL
Intervention: m-BACOD
Number of subjects: 1138
Study 7515652 — intervention group
Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 1138
Study 7515652 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 1138
Study 3079054 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 69
Study 3079054 — intervention group
Group type: COMPARATOR
Intervention: No Prednisone
Number of subjects: 69
Study 28678568 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 27
Study 28678568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 27466236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (2400 mg/day for 4 or 12 weeks)
Number of subjects: 12
Study 24916786 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making intervention with continuing medical education (CME) and patient activation tools.
Number of subjects: 355
Study 24916786 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up study phase.
Number of subjects: 355
Study 24916786 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation intervention.
Number of subjects: 355
Study 24916786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention by study phase interaction.
Number of subjects: 355
Study 24916786 — intervention group
Group type: COMPARATOR
Intervention: Comparison group with only CME.
Number of subjects: 355
Study 23819220 — intervention group
Group type: EXPERIMENTAL
Intervention: Sancai Needling - EA
Number of subjects: 60
Study 23819220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ashi-point - EA
Number of subjects: 60
Study 23819220 — intervention group
Group type: COMPARATOR
Intervention: Routine EA treatment
Number of subjects: 60
Study 20948493 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive biofeedback electrical stimulation
Number of subjects: 30
Study 18258367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 12
Study 18258367 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 12
Study 18258367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16361594 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 80
Study 16361594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12798752 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic artery occlusion (HAO) followed by intraportal 5‐fluorouracil (5‐Fu) infusion (1000 mg/m(2) for 5 days every sixth week)
Number of subjects: 39
Study 12798752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial 5‐Fu infusion + Leucovorin (100 mg i.v. for 2 days every second week) (HAI)
Number of subjects: 39
Study 12798752 — intervention group
Group type: COMPARATOR
Intervention: Comparison of survival between HAO and HAI groups
Number of subjects: 39
Study 12798752 — intervention group
Group type: COMPARATOR
Intervention: Time to progression
Number of subjects: 39
Study 10724201 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials with adequate randomization and reporting
Number of subjects: 73
Study 10724201 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple randomization
Number of subjects: 73
Study 10724201 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials
Number of subjects: 73
Study 10724201 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials reporting sample size and statistical power considerations
Number of subjects: 73
Study 8865594 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.83 N keyboard
Number of subjects: 6
Study 8865594 — intervention group
Group type: COMPARATOR
Intervention: 0.28 N keyboard
Number of subjects: 6
Study 1735268 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry at 30 degrees recumbency angle
Number of subjects: 16
Study 1735268 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry at 60 degrees recumbency angle
Number of subjects: 16
Study 1735268 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study 3928215 — intervention group
Group type: EXPERIMENTAL
Intervention: tocainide hydrochloride (200-600 mg daily)
Number of subjects: 32
Study 28580795 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed nutrition intervention
Number of subjects: 321
Study 28580795 — intervention group
Group type: COMPARATOR
Intervention: Self-directed exercise intervention
Number of subjects: 321
Study 26983011 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary alpha-amylase (sAA)
Number of subjects: 47
Study 26983011 — intervention group
Group type: EXPERIMENTAL
Intervention: Free cortisol
Number of subjects: 47
Study 26983011 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory IgA (sIgA)
Number of subjects: 47
Study 26983011 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between cortisol and sIgA
Number of subjects: 47
Study 26983011 — intervention group
Group type: COMPARATOR
Intervention: Comparison to healthy individuals
Number of subjects: 47
Study 25464675 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass index
Number of subjects: 733
Study 25464675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass index
Number of subjects: 733
Study 25464675 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 733
Study 25464675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat free mass index
Number of subjects: 733
Study 25464675 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat
Number of subjects: 733
Study 22422577 — intervention group
Group type: EXPERIMENTAL
Intervention: MitraClip intervention
Number of subjects: 30
Study 20167156 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease management program focused on blood pressure reduction
Number of subjects: 60
Study 17768053 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenretinide
Number of subjects: 10
Study 17768053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17768053 — intervention group
Group type: EXPERIMENTAL
Intervention: E2
Number of subjects: 10
Study 17768053 — intervention group
Group type: COMPARATOR
Intervention: CEE
Number of subjects: 10
Study 19298039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetabular center axis (ACA) registration technique
Number of subjects: 34
Study 19298039 — intervention group
Group type: COMPARATOR
Intervention: Anterior pelvic plane (APP) registration technique
Number of subjects: 34
Study 15043640 — intervention group
Group type: COMPARATOR
Intervention: Independent self-construal priming
Number of subjects: 0
Study 15043640 — intervention group
Group type: COMPARATOR
Intervention: Interdependent self-construal priming
Number of subjects: 0
Study 15043640 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic self-construal
Number of subjects: 0
Study 11736967 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled postoperative oral feeding (PC group)
Number of subjects: 105
Study 11736967 — intervention group
Group type: COMPARATOR
Intervention: Fixed regimen postoperative oral feeding (FR group)
Number of subjects: 105
Study 9237935 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA supplementation at doses of 3.0 g/d and 6.0 g/d
Number of subjects: 29
Study 9237935 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA supplementation at doses of 3.0 g/d
Number of subjects: 29
Study 9237935 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical Western diets)
Number of subjects: 29
Study 8516499 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD)
Number of subjects: 811
Study 8516499 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 811
Study 2964992 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose HRP112 (25mg DMPA plus 5mg estradiol cypionate)
Number of subjects: 88
Study 2964992 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose HRP112 (12.5mg DMPA plus 2.5mg estradiol cypionate)
Number of subjects: 88
Study 2964992 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dose DMPA (25mg)
Number of subjects: 88
Study 2964992 — intervention group
Group type: EXPERIMENTAL
Intervention: Half dose DMPA (12.5mg)
Number of subjects: 88
Study 2964992 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestogen combination preparations
Number of subjects: 88
Study 2964992 — intervention group
Group type: COMPARATOR
Intervention: DMPA alone
Number of subjects: 88
Study 29557731 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroPage service (reminder messages to mobile phones)
Number of subjects: 38
Study 29557731 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-memory texts)
Number of subjects: 38
Study 30791701 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral photos
Number of subjects: 110
Study 30791701 — intervention group
Group type: EXPERIMENTAL
Intervention: Group selfies
Number of subjects: 110
Study 28541533 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐Marsh model
Number of subjects: 30
Study 28541533 — intervention group
Group type: EXPERIMENTAL
Intervention: Schnider model
Number of subjects: 30
Study 25869509 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol dark chocolate (HFDC; 1064mg flavanols/day for 6 weeks)
Number of subjects: 0
Study 25869509 — intervention group
Group type: COMPARATOR
Intervention: Low flavanol dark chocolate (LFDC; 88mg flavanols/day for 6 weeks)
Number of subjects: 0
Study 25869509 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol dark chocolate (HFDC)
Number of subjects: 0
Study 25869509 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol dark chocolate (HFDC) and Low flavanol dark chocolate (LFDC)
Number of subjects: 0
Study 25869509 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine (pre-incubation of platelets)
Number of subjects: 0
Study 22901564 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care test for comprehensive metabolic panel (n=5,154)
Number of subjects: 10244
Study 22901564 — intervention group
Group type: COMPARATOR
Intervention: Central laboratory testing (n=5,090)
Number of subjects: 10244
Study 21335691 — intervention group
Group type: EXPERIMENTAL
Intervention: Email notifications for sentinel health events sent to care managers
Number of subjects: 13454
Study 21335691 — intervention group
Group type: COMPARATOR
Intervention: Control group (no email notifications)
Number of subjects: 13454
Study 19245538 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly-l-lactic acid (PLA) injections administered every 2 weeks from week 0 (immediate group)
Number of subjects: 100
Study 19245538 — intervention group
Group type: COMPARATOR
Intervention: Poly-l-lactic acid (PLA) injections administered every 2 weeks from week 24 (deferred group)
Number of subjects: 100
Study 16308413 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training for 6 months
Number of subjects: 104
Study 16308413 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study 14760045 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant photography included in referral letters
Number of subjects: 136
Study 14760045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instant photography)
Number of subjects: 136
Study 11501509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(‐1) ointment applied twice daily
Number of subjects: 0
Study 11501509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol combined with UVB phototherapy
Number of subjects: 0
Study 11501509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol combined with betamethasone valerate (each applied separately, once daily)
Number of subjects: 0
Study 11501509 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(‐1) ointment
Number of subjects: 0
Study 9532517 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg once a day
Number of subjects: 0
Study 9532517 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg once a day
Number of subjects: 0
Study 9532517 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg twice a day
Number of subjects: 0
Study 9532517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8300487 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised nifedipine 5 mg
Number of subjects: 20
Study 8300487 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolised verapamil 5 mg
Number of subjects: 20
Study 3572619 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate‐based formula (Isomil with Iron)
Number of subjects: 36
Study 3572619 — intervention group
Group type: COMPARATOR
Intervention: Cow milk protein‐based formula (Similac with Iron)
Number of subjects: 36
Study 31870942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol (1 mg intravenously)
Number of subjects: 32
Study 31870942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30200398 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g of dark chocolate containing 70% cocoa
Number of subjects: 84
Study 30200398 — intervention group
Group type: COMPARATOR
Intervention: 2 g of milk chocolate
Number of subjects: 84
Study 27555754 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (four-stage exercise program)
Number of subjects: 46
Study 24602210 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of Planned Behaviour (TPB) based online intervention
Number of subjects: 420
Study 24602210 — intervention group
Group type: COMPARATOR
Intervention: Information only
Number of subjects: 420
Study 24602210 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 420
Study 23338255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% CPC with positive‐pressure irrigation (PPI, Conventional, NaviTip(®))
Number of subjects: 40
Study 23338255 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CPC with positive‐pressure irrigation (PPI)
Number of subjects: 40
Study 23338255 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl with positive‐pressure irrigation (PPI)
Number of subjects: 40
Study 23338255 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl with negative‐pressure irrigation system (NPI, EndoVac(®))
Number of subjects: 40
Study 23338255 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC
Number of subjects: 40
Study 23338255 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 40
Study 23338255 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 40
Study 20513644 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 20
Study 20513644 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 20
Study 20513644 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched children with tension type headache)
Number of subjects: 20
Study 18981372 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CAG repeat number in patients with HD
Number of subjects: 517
Study 18981372 — intervention group
Group type: EXPERIMENTAL
Intervention: R6/2 mouse model with larger CAG repeat length
Number of subjects: 517
Study 15979994 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg Triptorelin (GnRH agonist)
Number of subjects: 106
Study 15979994 — intervention group
Group type: COMPARATOR
Intervention: 10 000 IU urinary HCG
Number of subjects: 106
Study 11227971 — intervention group
Group type: EXPERIMENTAL
Intervention: 50%/50% tilt biphasic waveform
Number of subjects: 60
Study 11227971 — intervention group
Group type: COMPARATOR
Intervention: 65%/65% tilt biphasic waveform
Number of subjects: 60
Study 9688055 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately stressed capsules
Number of subjects: 9
Study 9688055 — intervention group
Group type: COMPARATOR
Intervention: Unstressed capsules
Number of subjects: 9
Study 7748864 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (Strip mutans test for caries risk assessment)
Number of subjects: 528
Study 7748864 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 528
Study 3176071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone at 250 ppm
Number of subjects: 137
Study 3176071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl ethyl ketone (MEK) at 200 ppm
Number of subjects: 137
Study 3176071 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone at 125 ppm with MEK at 100 ppm
Number of subjects: 137